HDV ELISA Kits

HDV (Hepatitis D Virus) ELISA Kits are immunoassays developed for the detection and quantification of HDV-specific antibodies (anti-HDV IgG and IgM) or HDV antigens in biological samples such as serum and plasma. Hepatitis D, also known as delta hepatitis, is a liver infection caused by HDV, which requires the presence of hepatitis B virus (HBV) for replication. Detecting HDV antibodies or antigens is crucial for diagnosing HDV co-infection or superinfection in HBV patients, understanding disease progression, and monitoring patient response to antiviral treatments.

Content

HDV ELISA Kits generally include:

• Microplates pre-coated with HDV antigens or capture antibodies specific to HDV proteins, depending on the assay type (antibody or antigen detection).
• Detection antibodies, typically enzyme-conjugated (e.g., with horseradish peroxidase), which enable a measurable signal through chromogenic or fluorometric reactions.
• Standards and controls to ensure accurate quantification and standardization across different samples.
• Buffers and reagents, including wash, blocking, and substrate solutions, optimized to improve assay sensitivity and reduce background interference.

Applications

HDV ELISA Kits are widely used in:

• Clinical diagnostics: Detecting HDV-specific antibodies to diagnose co-infection or superinfection in individuals with hepatitis B, which is crucial for disease management and prognosis.
• Epidemiology and public health research: Monitoring HDV prevalence and transmission rates, especially in populations at high risk for HBV and HDV co-infection.
• Vaccine and therapeutic research: Studying immune response to potential HDV vaccines or therapies, as well as evaluating antiviral treatments targeting HDV.
• Disease progression and monitoring: Assessing HDV markers to understand the progression of HDV infection in HBV patients, particularly for identifying chronic infection or liver damage.

HDV ELISA Kits provide a reliable and sensitive method for detecting HDV infection, supporting research, diagnostics, and the development of therapies to manage and prevent hepatitis D in HBV-positive individuals.